ASP2074 for Solid Tumors
Trial Summary
What is the purpose of this trial?
This trial tests a new drug called ASP2074 for adults with advanced cancers that have spread and no longer respond to standard treatments. The drug is given through an infusion, and the study will find the best dose and check for side effects. Patients will be closely monitored throughout the treatment.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot participate if you require systemic steroid therapy or other immunosuppressive therapy within 14 days before starting the study treatment, unless it's a low dose or for specific purposes like imaging contrast.
How does the drug ASP2074 differ from other treatments for solid tumors?
ASP2074 is unique because it may involve a novel mechanism of action or target specific pathways in solid tumors, potentially similar to how PARP inhibitors target DNA repair pathways. This could make it effective for tumors with specific genetic profiles, offering a new option where standard treatments are limited.12345
Research Team
Senior Medical Director
Principal Investigator
Astellas Pharma Global Development, Inc.
Eligibility Criteria
Adults with advanced solid tumors that have spread and are not responding to standard treatments can join this trial. They must be in good physical condition (ECOG Status of 0 or 1), have recovered from previous therapies, agree to use contraception, and not be pregnant or breastfeeding. Specific cancers like colorectal, pancreatic, gastric cancer, esophageal or GEJ adenocarcinoma are included for certain parts of the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Part 1)
Participants receive escalating doses of ASP2074 to determine suitable doses for Part 2
Dose Expansion (Part 2)
Participants receive ASP2074 at doses determined from Part 1 to find a more accurate dose for future studies
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ASP2074
Find a Clinic Near You
Who Is Running the Clinical Trial?
Astellas Pharma Global Development, Inc.
Lead Sponsor
Tadaaki Taniguchi
Astellas Pharma Global Development, Inc.
Chief Medical Officer
M.D., Ph.D.
Naoki Okamura
Astellas Pharma Global Development, Inc.
Chief Executive Officer
Not available